Plasma exchange removes pro-aging blood factors
PrimaryCirculate Health's stated causal theory is that therapeutic plasma exchange can improve longevity-related biology by separating and replacing plasma, thereby reducing inflammatory and age-related factors circulating in blood. The implied mechanism is that some soluble plasma components contribute to biological aging or reduced healthspan, and lowering their burden should shift measurable biomarkers toward a younger or healthier profile. Testable predictions are that repeated TPE sessions should reduce circulating inflammatory or age-associated plasma factors, improve biological age measurements, and produce dose- or protocol-linked changes in longevity-relevant biomarkers. The supplied material cites a six-session clinical trial reported as published in Aging Cell with an average 2.6-year biological age reduction after treatment.
Popperian evaluation
The premise is biologically credible: plasma exchange can remove soluble blood components, and inflammation-linked plasma factors plausibly affect healthspan biology. The weaker step is causality. The supplied material supports factor removal better than it supports the claim that those removed factors drive aging itself.
Supporting evidence: Therapeutic plasma exchange separates and replaces plasma, reducing selected soluble factors circulating in blood.; The theory specifies inflammatory and age-associated soluble plasma components as the proposed causal class.
Counter evidence: The evidence context does not name the specific pro-aging factors removed.; The causal link between reduced plasma factor burden and slower aging is stated as an assumption with medium confidence.
The theory can explain a reported biological-age shift after six TPE sessions, but it does not yet beat simpler explanations cleanly. Biomarker changes could come from acute dilution, replacement fluid effects, transient inflammation changes, measurement noise, regression to the mean, or protocol-linked clinical care around the intervention. The theory needs factor-level evidence tied to the biomarker shift.
Supporting evidence: A cited six-session clinical trial was reported to show an average 2.6-year biological age reduction after treatment.; The proposed mechanism predicts lower inflammatory or age-associated plasma factors after repeated TPE sessions.
Counter evidence: The evidence context does not show that the same specific plasma factors fell and that their reduction mediated the biological-age change.; No alternative explanations are ruled out in the supplied material.
This is testable in a Popperian sense. The theory would take a real hit if repeated TPE failed to reduce named plasma factors, failed to improve pre-specified biological-age measures, or showed no dose or protocol relationship. The cleanest falsification would be a controlled trial with factor panels, biological-age endpoints, and a sham or active comparator.
Supporting evidence: The theory predicts reduced circulating inflammatory or age-associated plasma factors after repeated sessions.; The theory predicts improved biological age measurements.; The theory predicts dose- or protocol-linked changes in longevity-relevant biomarkers.
Counter evidence: The supplied predictions are directionally clear but do not define exact factor thresholds, assay panels, time windows, or minimum effect sizes.; Without pre-specified endpoints, a broad biomarker panel can make weak post-hoc wins look stronger than they are.